Methods and Compositions for Treating Ulcerative Colitis
AssigneeFinch Therapeutics Holdings LLC
InventorThomas Julius BORODY
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods and pharmaceutical compositions for treating ulcerative colitis (UC) in a subject in need thereof. In particular, the compositions described here comprise or are designed based on fecal bacteria associated with FMT-based UC treatment success or failure. Also provided are methods for screening patients for their suitability for a fecal bacteria-based UC treatment. Further provided are methods for screening fecal donors for optimized source materials for producing a fecal bacteria-based pharmaceutical composition.
Claims20
A pharmaceutical composition comprising viable non-pathogenic bacteria from one or more first microbial taxa selected from the group consisting of Clostridium cluster XVIII, Ruminococcus, Lachnospiraceae, Roseburia inulinivorans, Eubacterium hallii, and any combination thereof, wherein said pharmaceutical composition contains no bacteria from one or more second microbial taxa selected from the group consisting of Fusobacterium, Sutterella, Haemophilus, Escherichia, Megamonas, Clostridium cluster XIVa, Prevotella, Dialister, Veillonella, and Bilophila.
A method for producing a pharmaceutical composition, said method comprising
- a) determining in a candidate fecal microbe source material the relative abundance of one or more bacterial markers selected from the group consisting of Bacteroides OTU187, Bacteroides fragilis, Bacteroides finegoldii, Clostridium cluster XlVa (OTU173), Streptococcus (OTU56), Sutterella wadsworthensis, Bacteroides uniformis, and Bacteroides coprocola;
- b) selecting said candidate fecal microbe source material if the relative abundance of Bacteroides OTU187, Bacteroides fragilis, or Bacteroides finegoldii is above a pre-determined lowest limit, and/or if the relative abundance of Clostridium cluster XlVa (OTU173), Streptococcus (OTU56), Sutterella wadsworthensis, Bacteroides uniformis, or Bacteroides coprocola is below a pre-determined highest limit;
- and
- c) producing a pharmaceutical composition from said selected fecal microbe source material.
A method for selecting a fecal microbe source material, said method comprising
- a) Determining in a candidate fecal microbe source material the relative abundance of one or more markers from a metabolic pathway selected from the group consisting of fatty acid biosynthesis, propanoate metabolism, secondary bile acid biosynthesis, glycerophospholipid metabolism, biosynthesis of ansamycins, terpenoid backbone biosynthesis, bacterial chemotaxis, heme biosynthesis, and short chain fatty acid (SCFA) biosynthesis;
- and
- b) selecting said candidate fecal microbe source material based on the relative abundance of said one or more markers.
Dependencies are inferred from the claim text.